FDA Approved: MONJUVI — Supplemental Application (Incyte Corporation)

View source ↗

Summary

FDA approved a supplemental application for MONJUVI (tafasitamab-cxix) from Incyte, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)

Snippet

SUPPL AP for MONJUVI (TAFASITAMAB-CXIX)